Evaluation of the effect of oral Ivermectin on patients with COVID-19
Phase 3
- Conditions
- Corona virus.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20180922041089N4
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Patients 18 to 50 years
Infected by the COVID 19 virus
Patients with clinical symptoms, history of exposure to the patient and a positive RT-PCR test for Covid 19 from A laboratory or characteristic signs on a CT scan of the chest) with mild to moderate clinical manifestations according to the National Early Warning Score (NEWS) (mild: 1-4 / moderate: 5-6)
Obtaining informed written consent consciously
Exclusion Criteria
Severely ill and hospitalized in the intensive care unit
Patients who are unable to take oral medications
Patients with AST / ALT levels more than 5 times above normal
Pregnant patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improving clinical symptoms. Timepoint: Daily. Method of measurement: National Early Warning Score? (NEWS).;Reducing the length of hospitalization. Timepoint: Daily. Method of measurement: Counting.;Improving paraclinical indicators of the disease. Timepoint: Daily lymphocyte count - the last day of hospital CT scan. Method of measurement: Lymphocyte count - CT scan.
- Secondary Outcome Measures
Name Time Method ack of response to treatment and hospitalization in the ICU. Timepoint: Daily. Method of measurement: Assessing clinical manifestations.